Want to see IRLA full AI Analyst Report?
Top Page
IRulya Therapeutics
(NASDAQ:IRLA)
Select Model
Select Model
Rating:46Neutral
Price Target:
$29.00
▼(-6.24% Downside)
Action:Reiterated
Date:10/09/26
The score is held down primarily by weak financial performance (no revenue, widening losses, and ongoing cash burn), which outweighs the benefit of a currently low-debt balance sheet. Technicals are broadly neutral with soft momentum, valuation is constrained by loss-making fundamentals (negative P/E and no dividend), and recent corporate events are mixed—adding both strategic/financing flexibility and listing/dilution risk.
Positive Factors
Debt-free balance sheet
The latest trailing balance-sheet position shows no debt and positive equity, reducing interest burden and near-term creditor pressure. This gives Quince greater flexibility to direct available capital toward clinical development and other operating priorities while limiting leverage-related financial risk.
Negative Factors
Pre-revenue losses and cash burn
Quince has no commercial revenue base to offset development expenses, while losses have widened and free cash flow remains substantially negative. Continued cash consumption increases dependence on external financing and makes future financial performance highly dependent on clinical and funding outcomes.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
The latest trailing balance-sheet position shows no debt and positive equity, reducing interest burden and near-term creditor pressure. This gives Quince greater flexibility to direct available capital toward clinical development and other operating priorities while limiting leverage-related financial risk.
Read all positive factors
IRulya Therapeutics (IRLA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$32.27M
Dividend YieldN/A
Average Volume (3M)22.10K
Price to Earnings (P/E)―
Beta (1Y)0.76
Revenue GrowthN/A
EPS Growth43.02%
CountryUS
Employees38
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-68.91
Shares Outstanding1,017,063
10 Day Avg. Volume26,739
30 Day Avg. Volume22,104
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)-4.70
Price to Sales (P/S)0.00
P/FCF Ratio-4.02
Enterprise Value/Market Cap4.32
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.87K
Enterprise Value/Ebitda-1.93
Forecast
1Y Price Target
$75.63Price Target Upside144.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-9.78
Revenue Forecast (FY)N/A
IRulya Therapeutics Business Overview & Revenue Model
Company Description
Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Phase 3, for ...
How the Company Makes Money
As a clinical-stage biotechnology company, Quince Therapeutics does not have a stable, recurring product-revenue base from commercial drug sales (null for material marketed-product revenue streams). Its funding and cash inflows have historically b...
IRulya Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
41
Neutral
Cash Flow
24
Negative
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
IRulya Therapeutics Technical Analysis
Positive
30.93
Price Trends
30.41
Positive
24.95
Positive
98.79
Negative
Market Momentum
-0.12
Positive
56.90
Neutral
33.94
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IRLA, the sentiment is Positive. The current price of 30.93 is above the 20-day moving average (MA) of 29.42, above the 50-day MA of 30.41, and below the 200-day MA of 98.79, indicating a neutral trend. The MACD of -0.12 indicates Positive momentum. The RSI at 56.90 is Neutral, neither overbought nor oversold. The STOCH value of 33.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IRLA.
IRulya Therapeutics Risk Analysis
IRulya Therapeutics disclosed 83 risk factors in its most recent earnings report. IRulya Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
IRulya Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $63.16M | -0.68 | -53.22% | ― | ― | 55.84% | |
46 Neutral | $32.27M | -0.46 | -413.28% | ― | ― | 43.02% | |
46 Neutral | $161.16M | -1.43 | -39.64% | ― | ― | -6.70% | |
42 Neutral | $185.32M | -5.85 | -29.09% | ― | 8906.15% | 41.48% | |
33 Underperform | $12.85M | -2.05 | -64.46% | ― | ― | 33.15% |
* Healthcare Sector Average
IRLA
IRulya Therapeutics
31.73
-360.27
-91.91%
PLRX
Pliant Therapeutics
1.02
-0.47
-31.54%
NKTX
Nkarta
2.25
>-0.01
-0.44%
ADAG
Adagene
2.76
0.85
44.50%
ANEB
Anebulo Pharmaceuticals
0.32
-2.01
-86.42%
IRulya Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board ChangesDelistings and Listing Changes
Quince Relaunches as IRulya Therapeutics with New Leadership
Positive
Oct 9, 2026
On October 8–9, 2026, Quince Therapeutics implemented a broad relaunch as IRulya Therapeutics, including a legal name change, a move of its Nasdaq listing to the Capital Market under the new symbol IRLA, and relocation of its headquarters fr...
Business Operations and StrategyPrivate Placements and FinancingShareholder Meetings
Quince Shareholders Approve New Equity and Stock Plans
Positive
Oct 6, 2026
On October 6, 2026, Quince Therapeutics, Inc. held a special meeting of stockholders at which investors approved the company’s 2026 Equity Incentive Plan and 2026 Employee Stock Purchase Plan, establishing new share reserves and automatic an...
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and FinancingRegulatory Filings and ComplianceShareholder Meetings
Quince Therapeutics Announces Conditional Board Restructuring Plans
Neutral
Oct 2, 2026
On September 30, 2026, three directors of Quince Therapeutics tendered conditional resignations from the board, effective two business days after the October 6, 2026 special shareholders’ meeting, contingent on approval of three stockholder ...
Business Operations and StrategyExecutive/Board ChangesM&A Transactions
Quince Therapeutics Divests Italian Subsidiary, Refocuses Strategy
Negative
Sep 14, 2026
On September 8, 2026, Quince Therapeutics completed the sale of all equity in its Italian subsidiary Quince Therapeutics SpA, along with global intellectual property tied to its AIDE and eDSP technologies and all related machines and systems, to A...
Delistings and Listing ChangesFinancial DisclosuresRegulatory Filings and Compliance
Quince Therapeutics Faces Nasdaq Listing Compliance Challenges
Negative
Sep 4, 2026
On August 31, 2026, Quince Therapeutics received a Nasdaq notice that, based on its June 30, 2026 Form 10-Q, the company reported negative stockholders’ equity of $35.3 million, falling short of the $10 million minimum required under Nasdaq ...
Executive/Board Changes
Quince Therapeutics Announces Planned Presidential Leadership Transition
Neutral
Aug 27, 2026
Quince Therapeutics, Inc. reported that on August 23, 2026, the company and its President, Charles Ryan, agreed that his last day of employment will be September 8, 2026, marking a planned leadership transition. In connection with his departure, R...
Business Operations and StrategyFinancial DisclosuresM&A TransactionsPrivate Placements and FinancingRegulatory Filings and ComplianceShareholder MeetingsStock Split
Quince Plans Shareholder Vote on Major Stock Issuance
Neutral
Aug 17, 2026
Quince Therapeutics plans to convene a special shareholder meeting to seek approval for issuing a substantial number of new common shares upon conversion of its Series C Non-Voting Convertible Preferred Stock, as well as from related warrants and ...
Business Operations and StrategyExecutive/Board ChangesM&A TransactionsPrivate Placements and FinancingShareholder Meetings
Quince Therapeutics Announces Leadership Transition to Orphai Team
Neutral
Jul 31, 2026
On July 29, 2026, Quince Therapeutics announced that CEO and Chief Medical Officer Dirk Thye, who also serves on the board, and COO, Chief Business Officer and Chief Compliance Officer Brendan Hannah tendered conditional resignations, effective tw...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.